FDA clears investigational new drug application for Fragile X treatment
The FDA has cleared an investigational new drug application for a small molecule therapeutic to treat those with Fragile X syndrome, according to the manufacturer.In a press release, San Diego-based Spinogenix Inc. said SPG601 works by binding to BK (calcium activated potassium) synaptic channels and increasing their activation to restore synaptic function.